| First Author | Purbey PK | Year | 2024 |
| Journal | Cell Rep | Volume | 43 |
| Issue | 6 | Pages | 114289 |
| PubMed ID | 38833371 | Mgi Jnum | J:352683 |
| Mgi Id | MGI:7665934 | Doi | 10.1016/j.celrep.2024.114289 |
| Citation | Purbey PK, et al. (2024) Opposing tumor-cell-intrinsic and -extrinsic roles of the IRF1 transcription factor in antitumor immunity. Cell Rep 43(6):114289 |
| abstractText | Type I interferon (IFN-I) and IFN-gamma foster antitumor immunity by facilitating T cell responses. Paradoxically, IFNs may promote T cell exhaustion by activating immune checkpoints. The downstream regulators of these disparate responses are incompletely understood. Here, we describe how interferon regulatory factor 1 (IRF1) orchestrates these opposing effects of IFNs. IRF1 expression in tumor cells blocks Toll-like receptor- and IFN-I-dependent host antitumor immunity by preventing interferon-stimulated gene (ISG) and effector programs in immune cells. In contrast, expression of IRF1 in the host is required for antitumor immunity. Mechanistically, IRF1 binds distinctly or together with STAT1 at promoters of immunosuppressive but not immunostimulatory ISGs in tumor cells. Overexpression of programmed cell death ligand 1 (PD-L1) in Irf1(-/-) tumors only partially restores tumor growth, suggesting multifactorial effects of IRF1 on antitumor immunity. Thus, we identify that IRF1 expression in tumor cells opposes host IFN-I- and IRF1-dependent antitumor immunity to facilitate immune escape and tumor growth. |
